3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Glioblastoma
2
Brain Neoplasms
2
Adenocarcinoma of Lung
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Pemetrexed
5
ponatinib
4
pembrolizumab
4
Carboplatin
4
Cisplatin
3
130-nm albumin-bound paclitaxel
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
osimertinib
2
napabucasin
2
fludarabine
2
ficlatuzumab
2
entinostat
2
durvalumab
2
atezolizumab
2
Rituximab
2
Paclitaxel
2
Lutetium
2
Irinotecan
2
Immunotherapy
2
Imatinib Mesylate
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cyclophosphamide
2
Bortezomib
2
Bevacizumab
2
vorasidenib
1
siltuximab
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Histologic Type
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts